IL187578A0 - Process for preparing pure amorphous rosuvastatin calcium - Google Patents

Process for preparing pure amorphous rosuvastatin calcium

Info

Publication number
IL187578A0
IL187578A0 IL187578A IL18757807A IL187578A0 IL 187578 A0 IL187578 A0 IL 187578A0 IL 187578 A IL187578 A IL 187578A IL 18757807 A IL18757807 A IL 18757807A IL 187578 A0 IL187578 A0 IL 187578A0
Authority
IL
Israel
Prior art keywords
rosuvastatin calcium
pure amorphous
preparing pure
amorphous rosuvastatin
preparing
Prior art date
Application number
IL187578A
Other languages
English (en)
Original Assignee
Lek Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37440674&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL187578(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lek Pharmaceuticals filed Critical Lek Pharmaceuticals
Publication of IL187578A0 publication Critical patent/IL187578A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL187578A 2005-06-24 2007-11-22 Process for preparing pure amorphous rosuvastatin calcium IL187578A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI200500187 2005-06-24
PCT/EP2006/006008 WO2006136408A2 (en) 2005-06-24 2006-06-22 Process for preparing pure amorphous rosuvastatin calcium

Publications (1)

Publication Number Publication Date
IL187578A0 true IL187578A0 (en) 2008-03-20

Family

ID=37440674

Family Applications (1)

Application Number Title Priority Date Filing Date
IL187578A IL187578A0 (en) 2005-06-24 2007-11-22 Process for preparing pure amorphous rosuvastatin calcium

Country Status (12)

Country Link
US (1) US8207333B2 (enExample)
EP (1) EP1915349B2 (enExample)
JP (1) JP5416403B2 (enExample)
CN (1) CN101203496B (enExample)
AU (1) AU2006261088B2 (enExample)
CA (1) CA2611920C (enExample)
ES (1) ES2564807T5 (enExample)
HU (1) HUE027012T2 (enExample)
IL (1) IL187578A0 (enExample)
PL (1) PL1915349T5 (enExample)
SI (1) SI1915349T1 (enExample)
WO (1) WO2006136408A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2870593B2 (ja) 1997-02-03 1999-03-17 日本電気株式会社 焦点誤差検出器
WO2005023778A2 (en) 2003-08-28 2005-03-17 Teva Pharmaceutical Industries Ltd. Process for preparation of rosuvastatin calcium
US7777034B2 (en) 2003-11-24 2010-08-17 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
EP1689723B1 (en) 2003-12-02 2011-04-27 Teva Pharmaceutical Industries, Ltd. Reference standard for characterization of rosuvastatin
CA2591439C (en) 2005-02-22 2013-03-26 Teva Pharmaceutical Industries Ltd. Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
CN102807530B (zh) * 2005-06-24 2015-08-05 力奇制药公司 制备不含杂质的无定型罗苏伐他汀钙的方法
MX2007004427A (es) 2005-08-16 2007-06-14 Teva Pharma Intermedio de rosuvastatina cristalina.
US7994178B2 (en) 2006-09-18 2011-08-09 Teva Pharmaceutical Industries, Ltd. Crystalline rosuvastatin calcium and compositions thereof for treatment of hyperlipidaemia
WO2008053334A2 (en) * 2006-10-31 2008-05-08 Aurobindo Pharma Limited An improved process for preparing rosuvastatin calcium
EP2125754B1 (en) * 2007-02-08 2012-04-11 Aurobindo Pharma Limited Process for preparation of rosuvastatin calcium
US20090069563A1 (en) 2007-07-12 2009-03-12 Valerie Niddam-Hildesheim Rosuvastatin intermediates and their preparation
WO2009143776A1 (zh) 2008-05-27 2009-12-03 常州制药厂有限公司 瑞舒伐他汀钙盐的制备方法及其中间体
WO2010035284A2 (en) * 2008-09-26 2010-04-01 Matrix Laboratories Ltd An improved process for the preparation of rosuvastatin calcium
EP2387566B1 (en) * 2009-01-14 2014-05-07 KRKA, tovarna zdravil, d.d., Novo mesto Process for the preparation of rosuvastatin
AU2010205464A1 (en) * 2009-01-15 2011-08-18 Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag Process for the preparation of rosuvastatin salts
EP2467363A1 (en) 2009-08-17 2012-06-27 Aurobindo Pharma Limited Process for the manufacture of rosuvastatin calcium using crystalline rosuvastatin ethyl ester
HU230987B1 (hu) 2010-11-29 2019-08-28 Egis Gyógyszergyár Nyrt. Eljárás nagy tisztaságú gyógyszeripari intermedierek előállítására
FR2970178B1 (fr) 2011-01-07 2014-06-20 Liliane Therese Jacquot Promedicaments pour une delivrance specifique au niveau du foie et une meilleure tolerance
CN102070537B (zh) * 2011-01-28 2012-01-11 海南美大制药有限公司 一种瑞舒伐他汀钙化合物及其新制法
WO2013046222A2 (en) * 2011-08-10 2013-04-04 Glenmark Generics Limited A process for the preparation of amorphous rosuvastatin calcium
CN103709107B (zh) * 2012-09-29 2016-04-20 安徽省庆云医药化工有限公司 瑞舒伐他汀甲酯的新晶型及其制备方法
CN104370827B (zh) * 2013-08-13 2016-09-07 天津汉瑞药业有限公司 瑞舒伐他汀钙化合物
WO2015119261A1 (ja) * 2014-02-06 2015-08-13 株式会社エーピーアイ コーポレーション ロスバスタチンカルシウム及びその中間体の製造方法
WO2015123352A1 (en) 2014-02-13 2015-08-20 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
CN111788196A (zh) * 2018-01-09 2020-10-16 配体药物公司 缩醛化合物及其治疗用途
CN108398501A (zh) * 2018-03-02 2018-08-14 海南通用三洋药业有限公司 一种检测瑞舒伐他汀钙有关物质的方法
CN108675931A (zh) * 2018-05-18 2018-10-19 合肥合源药业有限公司 一种低钡他汀钙及其制备方法
CN111170950A (zh) * 2020-01-16 2020-05-19 河南豫辰药业股份有限公司 一种瑞舒伐他汀钙盐的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
GB9903472D0 (en) * 1999-02-17 1999-04-07 Zeneca Ltd Chemical process
GB0003305D0 (en) * 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
WO2005023778A2 (en) 2003-08-28 2005-03-17 Teva Pharmaceutical Industries Ltd. Process for preparation of rosuvastatin calcium
EP1678148A1 (en) * 2003-10-22 2006-07-12 Ranbaxy Laboratories Limited Process for the preparation of amorphous rosuvastatin calcium
WO2005054207A1 (en) 2003-12-04 2005-06-16 Glenmark Pharmaceuticals Limited Process for the preparation of pyrimidine derivatives
EP1737828A1 (en) 2004-01-19 2007-01-03 Ranbaxy Laboratories Limited Amorphous magnesium salts of rosuvastatin
WO2006035277A2 (en) 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Novel processes for preparing amorphous rosuvastatin calcium and a novel polymorphic form of rosuvastatin sodium

Also Published As

Publication number Publication date
EP1915349A2 (en) 2008-04-30
ES2564807T3 (es) 2016-03-29
WO2006136408A3 (en) 2007-04-19
PL1915349T5 (pl) 2019-02-28
CN101203496A (zh) 2008-06-18
ES2564807T5 (es) 2019-02-26
AU2006261088B2 (en) 2012-11-08
US8207333B2 (en) 2012-06-26
CA2611920A1 (en) 2006-12-28
EP1915349B1 (en) 2015-12-09
CN101203496B (zh) 2011-04-20
SI1915349T1 (sl) 2016-05-31
JP2008543899A (ja) 2008-12-04
PL1915349T3 (pl) 2016-05-31
WO2006136408A2 (en) 2006-12-28
US20080188504A1 (en) 2008-08-07
CA2611920C (en) 2015-05-05
JP5416403B2 (ja) 2014-02-12
AU2006261088A1 (en) 2006-12-28
EP1915349B2 (en) 2018-09-12
HUE027012T2 (en) 2016-10-28

Similar Documents

Publication Publication Date Title
IL187578A0 (en) Process for preparing pure amorphous rosuvastatin calcium
IL187483A0 (en) Process for preparing amorphous rosuvastatin calcium free of impurities
IL183528A0 (en) Process for preparing rosuvastatin
PL1727795T3 (pl) Sposób wytwarzania soli wapniowej atorwastatyny w formie bezpostaciowej
PL1923359T3 (pl) Sposób wytwarzania fiolek
IL182474A0 (en) Process for forming amorphous atorvastatin
EP1828170A4 (en) PROCESS FOR PREPARING VORICONAZOLE
IL197327A0 (en) Crystalline rosuvastatin calcium
IL183239A0 (en) Process for preparing amorphous valsartan
IL209568A0 (en) Pyrimidine compound crystal or amorphous form and process for producing the same
IL184874A0 (en) Process for preparing protected amidines
IL185872A0 (en) Process for preparing levetiracetam
ZA200608083B (en) Process for preparing 5-methyl-2-furfural
TWI372145B (en) Process for preparing alkylanilides
EP1751123A4 (en) PROCESS FOR PREPARING IRBESARTAN
ZA200806049B (en) Cefdinir synthesis process
IL182211A0 (en) Process for preparing purine compounds
GB0614245D0 (en) Synthesis process
IL189574A0 (en) Process for preparing 1-substituted-5-acylimidazole compounds
IL178574A0 (en) Process for forming amorphous atorvastatin calcium
EP1856101A4 (en) PROCESS FOR PREPARING AMORPHENE SALTS
EP1907474A4 (en) PROCESS FOR PRODUCING A POLYOLEFIN
IL186460A0 (en) Process for preparing bicyclic compounds
IL183804A0 (en) Process for preparing substituted 2-alkoxycarbonyl-3-aminothiophenes
EP1870408A4 (en) A NEW METHOD FOR THE PRODUCTION OF RAMOSETRON OR ITS SALT

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed